Orolingual angioedema during or after thrombolysis for cerebral ischemia

Stroke

Volumn 47, Issue 7, 2016, Pages 1825-1830

  Myslimi, Fjorda ^a,c   Caparros, François ^a   Dequatre Ponchelle, Nelly ^a   Moulin, Solène ^a,b   Gautier, Sophie ^a,b   Girardie, Patrick ^a   Cordonnier, Charlotte ^a,b   Bordet, Régis ^a,b   Leys, Didier ^a,b  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c Maastricht University   (Albania)

Author keywords

angioedema; cerebral hemorrhage; ischemia; odds ratio; outcome

Indexed keywords

ALTEPLASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OROLINGUAL ANGIOEDEMA; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RANKIN SCALE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; ADVERSE EFFECTS; AIRWAY OBSTRUCTION; ANGIOEDEMA; BRAIN CORTEX; CEREBRAL INFARCTION; CHEMICALLY INDUCED; FIBRINOLYTIC THERAPY; LIP DISEASES; MIDDLE AGED; TONGUE DISEASES; VASCULARIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AIRWAY OBSTRUCTION; ANGIOEDEMA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRAIN ISCHEMIA; CEREBRAL CORTEX; CEREBRAL INFARCTION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; LIP DISEASES; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TONGUE DISEASES;

EID: 84969799131     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.013334     Document Type: Article

References (32)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995 333 1581 1587. doi: 10.1056/NEJM199512143332401.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, ECASS Investigators Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008 359 1317 1329. doi: 10.1056/NEJMoa0804656.
3. Wardlaw JM, Murray V, Berge E, del Zoppo G, Sandercock P, Lindley RL, Recombinant tissue plasminogen activator for acute ischaemic stroke: An updated systematic review and meta-Analysis. Lancet 2012 379 2364 2372. doi: 10.1016/S0140-6736(12)60738-7.
4. Dequatre-Ponchelle N, Touzani H, Banh A, Girard-Buttaz I, Coche R, Dobbelaere P, Rate of intravenous thrombolysis for acute ischaemic stroke in the North-of-France region and evolution over time. J Neurol 2014 261 1320 1328. doi: 10.1007/s00415-014-7344-5.
5. Bodenant M, Leys D, Debette S, Cordonnier C, Dumont F, Hénon H, Intravenous thrombolysis for acute cerebral ischaemia: comparison of outcomes between patients treated at working versus nonworking hours. Cerebrovasc Dis 2010 30 148 156. doi: 10.1159/000316058.
6. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998 352 1245 1251. doi: 10.1016/S0140-6736(98)08020-9.
7. The European Stroke Organisation (ESO) executive committee Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008 25 457 507. doi: 10.1159/000131083.
8. Lyden P, Brott T, Tilley B, Welch KM, Mascha EJ, Levine S, Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994 25 2220 2226
9. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 24 35 41. doi: 10.1161/01.STR.24.1.35.
10. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J, Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988 19 604 607. doi: 10.1161/01.STR.19.5.604.
11. Zinkstok SM, Engelter ST, Gensicke H, Lyrer PA, Ringleb PA, Artto V, Safety of thrombolysis in stroke mimics: results from a multicenter cohort study. Stroke 2013 44 1080 1084. doi: 10.1161/STROKEAHA.111.000126.
12. Wallon D, Girardie P, Bombois S, Lucas C, Angioneurotic orolingual oedema following thrombolysis in acute ischaemic stroke. BMJ Case Rep. doi: 10.1136/bcr.06.2010.3094.
13. Hill MD, Lye T, Moss H, Barber PA, Demchuk AM, Newcommon NJ, Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology 2003 60 1525 1527
14. Correia AS, Matias G, Calado S, Lourenço A, Viana-Baptista M, Orolingual angiodema associated with alteplase treatment of acute stroke: A reappraisal. J Stroke Cerebrovasc Dis 2015 24 31 40. doi: 10.1016/j.jstrokecerebrovasdis.2014.07.045.
15. Lekoubou A, Philippeau F, Derex L, Olaru A, Gouttard M, Vieillart A, Audit report and systematic review of orolingual angioedema in post-Acute stroke thrombolysis. Neurol Res 2014 36 687 694. doi: 10.1179/1743132813Y.0000000302.
16. Lin SY, Tang SC, Tsai LK, Yeh SJ, Hsiao YJ, Chen YW, Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use. Eur J Neurol 2014 21 1285 1291. doi: 10.1111/ene.12472.
17. Werner R, Keller M, Woehrle JC, Facial angioedema and stroke. Cerebrovasc Dis 2014 38 101 106. doi: 10.1159/000365205.
18. Ottomeyer C, Sick C, Hennerici MG, Szabo K, [Orolingual angioedema under systemic thrombolysis with rt-PA: An underestimated side effect]. Nervenarzt 2009 80 459 463. doi: 10.1007/s00115-009-2685-5.
19. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005 172 1307 1312. doi: 10.1503/cmaj.1041561.
20. Engelter ST, Fluri F, Buitrago-Téllez C, Marsch S, Steck AJ, Rüegg S, Life-Threatening orolingual angioedema during thrombolysis in acute ischemic stroke. J Neurol 2005 252 1167 1170. doi: 10.1007/s00415-005-0789-9.
21. Yayan J, Lingual angioedema with macroglossia during the treatment of acute ischemic stroke with alteplase. Int J Gen Med 2012 5 183 186. doi: 10.2147/IJGM.S29200.
22. Winkler DT, Fluri F, Fuhr P, Wetzel SG, Lyrer PA, Ruegg S, Thrombolysis in stroke mimics: frequency, clinical characteristics, and outcome. Stroke 2009 40 1522 1525. doi: 10.1161/STROKEAHA.108.530352.
23. Chernyshev OY, Martin-Schild S, Albright KC, Barreto A, Misra V, Acosta I, Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology 2010 74 1340 1345. doi: 10.1212/WNL.0b013e3181dad5a6.
24. Guillan M, Alonso-Canovas A, Gonzalez-Valcarcel J, Garcia Barragan N, Garcia Caldentey J, Hernandez-Medrano I, Stroke mimics treated with thrombolysis: further evidence on safety and distinctive clinical features. Cerebrovasc Dis 2012 34 115 120. doi: 10.1159/000339676.
25. Förster A, Griebe M, Wolf ME, Szabo K, Hennerici MG, Kern R, How to identify stroke mimics in patients eligible for intravenous thrombolysis? J Neurol 2012 259 1347 1353. doi: 10.1007/s00415-011-6354-9.
26. Tsivgoulis G, Alexandrov AV, Chang J, Sharma VK, Hoover SL, Lao AY, Safety and outcomes of intravenous thrombolysis in stroke mimics: A 6-year, single-care center study and a pooled analysis of reported series. Stroke 2011 42 1771 1774. doi: 10.1161/STROKEAHA.110.609339.
27. Schwammenthal Y, Tsabari R, Bakon M, Orion D, Merzeliak O, Tanne D, Trombolysis in acute stroke. Isr Med Assoc J 2006 8 784 787
28. Chang J, Teleb M, Yang JP, Alderazi YJ, Chapple K, Frey JL, A model to prevent fibrinolysis in patients with stroke mimics. J Stroke Cerebrovasc Dis 2012 21 839 843. doi: 10.1016/j.jstrokecerebrovasdis.2011.04.018.
29. Hurford R, Rezvani S, Kreimei M, Herbert A, Vail A, Parry-Jones AR, Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke. J Neurol Neurosurg Psychiatry 2015 86 520 523. doi: 10.1136/jnnp-2014-308097.
30. Molinaro G, Gervais N, Adam A, Biochemical basis of angioedema associated with recombinant tissue plasminogen activator treatment: An in vitro experimental approach. Stroke 2002 33 1712 1716. doi: 10.1161/01.STR.0000017284.77838.87.
31. Gröger M, Lebesgue D, Pruneau D, Relton J, Kim SW, Nussberger J, Release of bradykinin and expression of kinin B2 receptors in the brain: role for cell death and brain edema formation after focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2005 25 978 989. doi: 10.1038/sj.jcbfm.9600096.
32. Laible M, Jenetzky E, Möhlenbruch M, Ringleb PA, Rizos T, Repeated intravenous treatment with recombinant tissue-Type plasminogen activator in patients with acute ischemic stroke. Eur Neurol 2015 74 127 134. doi: 10.1159/000439048.